Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
On a field-in-field breast tangent plan do you have a minimum MU you accept for a subfield?
Answer from: Radiation Oncologist at Community Practice
I usually avoid sub field with MU, less than 4-5 as adds little to plan quality and increases treatment time.
Sign in or Register to read more
15098
Related Questions
Do young, early-stage breast cancer patients with pCR to chemoimmunotherapy still benefit from PMRT?
For a young female (<40) with HR-/HER2+ cT1-2N1, ypT1aN0 s/p mastectomy with SLNB, would you offer PMRT?
Would you consider radiation omission for a patient with a Stage I breast cancer with an elevated Oncotype Dx?
Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?
When treating early stage breast cancer with adjuvant RT, what risk factors would lead you to include the level 1 and 2 axilla in patients with pN0(i+) disease?
How do you choose between ALND and RNI in the setting of LYMPHA or S-Lympha surgery?
How do you advise patients on cardiotoxicity when they are expected to receive a low mean heart dose and low cardiac substructure doses with their radiation plan?
Would you recommend PMRT in a patient with a triple negative cT2N0, ypT2N0 metaplastic breast cancer s/p NAC, mastectomy, and SLNB?
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
Is stage I B/L breast, ER+ cancer a contraindication to breast radiation omission after breast conservation surgery?